A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)
NCT07645248
This study is recruiting at 12 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
This study aims to generate additional safety data on the propellant component of the reformulated product by comparing metered dose inhaler (MDIs) containing HFA-152a (test) with HFA-134a (reference).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Asthma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- GlaxoSmithKline
- Last updated on ClinicalTrials.gov
- September 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 4
- GSK Investigational Site · Aventura, FL
- GSK Investigational Site · Miami, FL
- GSK Investigational Site · Miami, FL
- GSK Investigational Site · Naples, FL
Kentucky · 1
- GSK Investigational Site · Owensboro, KY
Missouri · 1
- GSK Investigational Site · Columbia, MO
Nevada · 1
- GSK Investigational Site · Henderson, NV
Oregon · 1
- GSK Investigational Site · Medford, OR
South Carolina · 2
- GSK Investigational Site · Spartanburg, SC
- GSK Investigational Site · Spartanburg, SC
Texas · 2
- GSK Investigational Site · Cypress, TX
- GSK Investigational Site · Tomball, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.